Leggett Thomas 4

What Happened

• Thomas Leggett, Chief Financial Officer of Stoke Therapeutics (STOK), received equity awards on 2026-02-17 totaling 100,000 derivative shares: a 60,000-share award with monthly vesting and a 40,000 restricted stock unit (RSU) award with annual vesting. Both entries are reported as awards (transaction code A) with a reported acquisition price of $0.00, meaning no cash was paid by the insider at grant. These are compensation awards, not open-market purchases or sales.

Key Details

• Transaction date: February 17, 2026; Form 4 filed February 19, 2026 (appears timely under Form 4 rules).
• Awards: 60,000 derivative shares (option-style; footnote F1) and 40,000 RSUs (footnotes F2 & F3); reported price $0.00 for each award.
• Vesting:
  • F1 (60,000): vests 1/48 of total award on March 15, 2026, then 1/48 each monthly anniversary thereafter (typical 4‑year monthly schedule), subject to continued service.
  • F2/F3 (40,000 RSUs): each RSU equals one contingent share; vests 1/4 annually with first tranche on February 15, 2027, subject to continued service.
• Shares owned after the transaction: not disclosed in the supplied filing details.
• Transaction code: A = Award/Grant. No 10b5-1 plan, tax‑withholding, or sale reported in this filing.

Context

• These entries are derivative compensation awards that only convert into actual shares as they vest (RSUs settle into shares; the option-style award vests over time). They do not represent an immediate purchase or sale and therefore are routine executive compensation rather than a direct market signal. Retail investors should note vesting schedules — the economic interest is realized only if and when awards vest and, for options, any exercise conditions are met.